FDA Grants Priority Review to Genentechs Cancer Immunotherapy TECENTRIQ Atezolizumab for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that the U.S. Food and Drug Administration FDA has accepted the companys supplemental Biologics License Application sBLA and granted Priority Review for T...